title: [Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].
abstract: The analytical and clinical validation of new biomarkers for the early detection of prostate is necessary. (-2)proPSA, total PSA and free PSA values are used to calculate a standardized PHI index linked to a higher probability of a positive biopsy in patients with PSA levels between 3-4 and 10 ng/L, the gray zone for prostate cancer diagnosis. The purpose of this study is to validate the analytical performance of the (-2)proPSA and to determine the predictive value of PHI for the early detection of prostate cancer. Analytical performances are correct. It is not necessary to dilute samples before analysis. The stability of (-2)proPSA is good until at least 3 hours at room temperature before centrifugation. The study of the PSAT, PSAL, (-2)proPSA and PHI values in a population of patients consulting for an early prostate cancer diagnosis shows that the index PHI is the most powerful predictive marker of cancer with an area under ROC curve of 0.70, whereas it is only 0.56 for total PSA.
authors.affiliation: Laboratoire de biologie spécialisée, Institut régional du cancer de Montpellier, France.
authors.forename: Pierre-Jean
authors.initials: PJ
authors.lastname: Lamy
authors.forename: Frédéric
authors.initials: F
authors.lastname: Montels
authors.forename: Diego
authors.initials: D
authors.lastname: Tosi
authors.forename: Benoit
authors.initials: B
authors.lastname: Leizour
authors.forename: Caroline
authors.initials: C
authors.lastname: Bascoul-Mollevi
authors.forename: Florence
authors.initials: F
authors.lastname: Castan
authors.forename: Sylvie
authors.initials: S
authors.lastname: Roques
authors.forename: Fabien
authors.initials: F
authors.lastname: Nielloud
authors.forename: Xavier
authors.initials: X
authors.lastname: Rebillard
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D001774:Blood Chemical Analysis / Q000379:methods / Q000592:standards; D001793:Blood Preservation / Q000379:methods / Q000592:standards; D055088:Early Detection of Cancer / Q000379:methods* / Q000592:standards; D006305:Health Status Indicators; D006801:Humans; D057230:Limit of Detection; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000737:chemistry; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D011498:Protein Precursors / Q000097:blood*; D055550:Protein Stability; D015203:Reproducibility of Results
chemical_list: D014408:Biomarkers, Tumor; D011498:Protein Precursors; D017430:Prostate-Specific Antigen
keywords: (-2)proPSA; PSA; Phi index; prostate cancer; screening; tumor markers